AbbVie Beats on Humira and Imbruvica, Raises 2016 EPS View
(Bloomberg) -- AbbVie sees 2016 adj EPS $4.73 to $4.83, saw $4.62-$4.82 (April 28), est. $4.75 (range $4.64-$4.82); cites performance year-to-date, sees “continued positive trends” for rest of year.
- 2Q adj EPS $1.26, est. $1.20 (range $1.19-$1.22); co. forecast $1.19-$1.21 (April 28)
- 2Q adj. rev. $6.43b vs est. $6.2b (range $6.07b-$6.41b)
- Humira $4.15b, est. $3.98b
- Imbruvica $439m, est. $432.7m
- Viekira Pak $419m, est. $406.7m
- Call 9am, 877-934-8565 pw ABBVIE; preview
Statement {NSN OB2QZG3MMTC0 }
Alert:
HALISTERSource: BFW (Bloomberg First Word)
Tickers ABBV US (AbbVie Inc)
4523 JP (Eisai Co Ltd)
To de-activate this alert, click
hereUUID: 7947283